All relevant data applied to perform the analyses in our study was provided in Supporting Information files.

Introduction {#sec005}
============

Pancreatic cancer is a digestive malignancy with extremely aggressive behavior. It is the fifth leading cause of cancer-related deathsworldwide, and the five-year survival rate of such cancer is approximately8% on the basis of latest data provided by Siegel RL, et al \[[@pone.0164150.ref001]\]. Chemotherapy and radiotherapy are not effective for PC due to several reasons, such as complex genetic mutations, hypoxic tolerance, and excessive fibrosis \[[@pone.0164150.ref002]\]. At present, the only available treatment for PC is radical operation; however, the rate of surgical resection is less than 20% because of the absence of obvious symptoms at the early stage \[[@pone.0164150.ref003]\].Therefore, to find novel therapeutic strategies based on molecular biomarkers of PC is extremely urgent. Recently, an increasing number of molecular contribute to the transformation and progression of PC were identified, some of these molecular was regarded as prognostic and/or therapeutic markers, such as MUC4, LSD1, and FHL2 \[[@pone.0164150.ref004]--[@pone.0164150.ref006]\].

MCM family is composed of ten proteins which primarily promote the process of DNA replication of eukaryotes \[[@pone.0164150.ref007]\]. MCM1 is an important member of MADS box transcription factor family, this protein affects the process of cell cycle, apoptosis, growth, and differentiationthrough regulating many gene activation \[[@pone.0164150.ref008]\]. The MCM2-7 heterohexamer complex was first detected in the yeast *Saccharomyces cerevisiae*\[[@pone.0164150.ref009]\], and the functions of this complex were extensively studied nowdays.MCM2-7interact with each other to form a functional DNA helicases which trigger the initial step of DNA synthesis \[[@pone.0164150.ref010], [@pone.0164150.ref011]\]. MCM8 and MCM9 were generally considered as additional members of MCM2-7 family \[[@pone.0164150.ref007]\]. Like MCM2-7 complex, MCM8 and MCM9 were also crucial components of the pre-replication complex. MCM8 and MCM9 were also involved in drivingthe initiation of Sphase \[[@pone.0164150.ref012], [@pone.0164150.ref013]\]. MCM10 is another necessary molecule for initializing the DNA synthesis due to its interaction with MCM2-7 complex\[[@pone.0164150.ref014], [@pone.0164150.ref015]\]. Furthermore, it has been reported that some members ofMCMs were abnormally up-regulated in various malignancies, and over-expression of them could promote the progression of malignant cells and predict the survival times of suffered patients \[[@pone.0164150.ref016]--[@pone.0164150.ref018]\]. However, the roles of MCMs in PC was absolutely unknown.

Here we will assess the expression of MCMs in PC according to the data provided by TCGA, and analyze the association between MCMs expression and the progression, prognosis of PC.

Methods and Materials {#sec006}
=====================

Clinicopathologic Features and MCMs Expression {#sec007}
----------------------------------------------

Clinicopathologic features and MCMs expression (level 3 data, log2(RSEM+1) transformed) for pancreatic cancer patients were downloaded from TCGA data portal (<http://cancergenome.nih.gov/>). The National Cancer Institute (NCI) and National Human Genome Research Institute (NHGRI) work with physicians who collect tissue for TCGA to gain approval with local Institutional Review Boards (IRBs). An IRB is a group of scientists, doctors, clergy and consumers who review and approve the research proposal for every research project that involves human subjects. 165 patients were finally included in our study, others were excluded due to the lack of critical information (such as overall survival time, age, gender, et al). Main clinicopathologic features for PC patients were shown in **[Table 1](#pone.0164150.t001){ref-type="table"}**. All patients were divided into low and high expression group according to the median value of each gene expression. Gene was defined as high expression if this gene expression was more than or equal to median value, otherwise it was defined as low expression.

10.1371/journal.pone.0164150.t001

###### Clinicopathologic features of the patients with PC.

![](pone.0164150.t001){#pone.0164150.t001g}

                                               Pancreatic Cancer Patients (n = 165)
  ------------ ------------------------------- --------------------------------------
  Age          Median age                      65
  Range        35--88                          
  Gender       Male                            90(54.55%)
  Female       75(45.45%)                      
  TMN stage    0/I/IIA                         0(0.00%)/20(12.12%)/25(15.15%)
  IIB/III/IV   113(68.48%)/4(2.42%)/3(1.82%)   

Statistical Analysis {#sec008}
--------------------

The different expression groups (high *vs*. low) was defined by the median value of MCMs expression. The association of MCMs expression with clinicopathologic indicators was accessed by Pearson χ^2^ test. The correction between MCMs expression and overall survival time was evaluated by Kaplan-Meier plots and log-rank tests, as well as disease free time. Independent prognostic factors were recognized byunivariate and multivariate Cox proportional hazard regression models were used to recognize. All statistical analyses were performed by SPSS 20.0 software. Differences between groups were considered significant at *P*\<0.05.

Results {#sec009}
=======

MCMs Expression and Association with Biomarkers for Tumor Biological Behaviors {#sec010}
------------------------------------------------------------------------------

As shown in [Fig 1](#pone.0164150.g001){ref-type="fig"}, all MCMs were generally determined in PC samples.

![The relative expression of MCM1-10 in 165 PC samples.\
(A) The relative expression of MCM1-5 in 165 PC samples. (B) The relative expression of MCM6-10 in 165 PC samples.](pone.0164150.g001){#pone.0164150.g001}

As MCMs were reported to participate in the synthesis of DNA, we firstly analyzed the association between MCMs and markers for S phase and proliferation. MCM2-7 complex, MCM8, and MCM10 expression was positively associated with CDK1 and CCNB1 expression which worked as critical proteins in S phase. Almost all assessed molecules were positively corrected with the proliferative biomarker Ki-67 in addition to MCM1. We further assessed the functions of MCMs in cell invasion, migration, and EMT. A few molecules were weakly or moderately associated with MMP2, MMP7, and MMP9; little correlation between MCMs expression and EMT biomarkers expression was observed. Furthermore, we evaluated the roles of MCMs in gemcitabine resistance, and analytic data suggested that most of these molecules over-expression was associated with gemcitabine resistance biomarker RRM1 in different degrees. All results in this aspect were shown in **[Table 2](#pone.0164150.t002){ref-type="table"}**. These results demonstrated that higher MCMs levels might be responsible for PC cell proliferation and gemcitabine resistance.

10.1371/journal.pone.0164150.t002

###### Association between MCMs and biomarkers for tumor biological behaviors.
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          CDK1    CCNB1    Ki67     RRM1     hENT     MMP2     MMP7     MMP9     ECAD    VIM      
  ------- ------- -------- -------- -------- -------- -------- -------- -------- ------- -------- --------
  MCM1    r       -0.162   -0.276   -0.104   -0.088   0.211    0.357    0.062    0.112   -0.291   0.36
  *P*     0.038   0.000    0.184    0.264    0.006    0.000    0.428    0.152    0.000   0.000    
  MCM2    r       0.639    0.675    0.606    0.666    -0.126   0.114    0.036    0.222   0.026    0.015
  *P*     0.000   0.000    0.000    0.000    0.106    0.145    0.643    0.004    0.738   0.850    
  MCM3    r       0.460    0.439    0.485    0.408    0.114    0.009    0.102    0.129   -0.055   0.028
  *P*     0.000   0.000    0.000    0.000    0.146    0.912    0.194    0.097    0.480   0.720    
  MCM4    r       0.660    0.681    0.678    0.667    -0.086   0.130    0.124    0.163   0.184    -0.123
  *P*     0.000   0.000    0.000    0.000    0.274    0.097    0.112    0.037    0.018   0.115    
  MCM5    r       0.419    0.382    0.409    0.341    0.024    0.106    0.082    0.401   -0.197   0.200
  *P*     0.000   0.000    0.000    0.000    0.760    0.175    0.298    0.000    0.011   0.010    
  MCM6    r       0.613    0.544    0.609    0.564    -0.029   0.423    0.235    0.330   -0.129   0.271
  *P*     0.000   0.000    0.000    0.000    0.707    0.000    0.002    0.000    0.097   0.000    
  MCM7    r       0.453    0.574    0.390    0.429    -0.124   -0.148   -0.141   0.060   -0.006   -0.181
  *P*     0.000   0.000    0.000    0.000    0.112    0.057    0.071    0.446    0.942   0.020    
  MCM8    r       0.509    0.469    0.542    0.472    -0.119   0.035    -0.053   0.179   -0.008   -0.149
  *P*     0.000   0.000    0.000    0.000    0.128    0.660    0.501    0.022    0.915   0.056    
  MCM9    r       0.067    -0.152   0.190    -0.081   0.054    0.135    0.287    0.113   0.044    -0.066
  *P*     0.394   0.052    0.015    0.302    0.489    0.083    0.000    0.149    0.579   0.406    
  MCM10   r       0.889    0.731    0.857    0.569    -0.038   0.230    0.339    0.321   0.172    -0.013
  *P*     0.000   0.000    0.000    0.000    0.625    0.003    0.000    0.000    0.027   0.868    

Association between MCMs Expression and Clinicopathologic Variables {#sec011}
-------------------------------------------------------------------

Analytic results suggested that MCM4 over-expression was detected in patients with aggressive T stage, and MCM9 was over-expressed in patients with lymph node metastasis (**[Table 3](#pone.0164150.t003){ref-type="table"}**). Furthermore, no other association between these genes expression and clinicopathologic features were observed (**[Table 3](#pone.0164150.t003){ref-type="table"}**). Results in this aspect suggested that MCM4 and MCM9 could be considered as biomarkers for PC progression.

10.1371/journal.pone.0164150.t003

###### Association between MCMs expression and clinicopathologic variables.
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                  Histology stage   N stage     T stage   TNM stage                     
  ------- ------- ----------------- ----------- --------- ----------- ---- ------- ---- ----
  MCM1    Low     54                29          25        58          16   67      23   60
  High    62      20                23          59        11          71   22      60   
  *P*     0.138                     0.770                 0.309            0.899        
  MCM2    Low     64                19          23        60          16   67      23   60
  High    52      30                25          57        11          71   22      60   
  *P*     0.054                     0.695                 0.309            0.899        
  MCM3    Low     61                22          23        60          17   66      23   60
  High    55      27                25          57        10          72   22      60   
  *P*     0.367                     0.695                 0.150            0.899        
  MCM4    Low     63                20          25        58          19   64      24   59
  High    53      29                23          59        8           74   21      61   
  *P*     0.113                     0.770                 **0.023**        0.634        
  MCM5    Low     62                21          27        56          15   68      25   58
  High    54      28                21          61        12          70   20      62   
  *P*     0.214                     0.328                 0.551            0.409        
  MCM6    Low     59                24          27        56          16   67      26   57
  High    57      25                21          61        11          71   19      63   
  *P*     0.825                     0.328                 0.309            0.240        
  MCM7    Low     63                20          22        61          17   66      22   61
  High    53      29                26          56        10          72   23      59   
  *P*     0.113                     0.462                 0.150            0.824        
  MCM8    Low     63                20          25        58          15   68      23   60
  High    53      29                23          59        12          70   22      60   
  *P*     0.113                     0.770                 0.551            0.899        
  MCM9    Low     64                19          30        53          16   67      27   56
  High    52      30                18          64        11          71   18      64   
  *P*     0.054                     **0.045**             0.309            0.127        
  MCM10   Low     61                22          22        60          17   66      22   61
  High    55      27                25          57        10          72   23      59   
  *P*     0.367                     0.695                 0.150            0.824        

Survival Outcomes and Multivariate Analysis {#sec012}
-------------------------------------------

Firstly, the influence of MCMs on disease free survival time was evaluated. A total of 140 patients with disease free survival time related data were enrolled in this section. Analytic results suggested that MCM2, 4, 6, 8, and 10 expression was significantly associated with disease free survival time (**[Fig 2A](#pone.0164150.g002){ref-type="fig"}**). Specifically patients with lower MCM2, 4, 6, 8, 10 levels had longer disease free survival time.And then, the association between MCMs and overall survival time was also assessed. Similar to disease free survival time, lower MCM2, 4, 8, 10 expression was markedly correlated with better overall survival (**[Fig 2B](#pone.0164150.g002){ref-type="fig"}**). Other molecules did not show any correlation with overall survival. Finally, independent prognostic factors was investigated by using Cox proportional hazard regression models. Results of univariate analysis demonstrated that not only some MCM proteins but also some clinicopathologic indicators corrected with overall survival, including T stage, N stage, and TNM stage (**[Table 4](#pone.0164150.t004){ref-type="table"}**). Multivariate analytic results suggested that MCM8 could independently predict the overall survival of PC (**[Table 4](#pone.0164150.t004){ref-type="table"}**).

![Survival analysis of PC patients correlated with MCM1-10 expression.\
(A) The association between MCM1-10 expression and disease free survival time. The higher expression of MCM2, 4, 6, 8, and 10 was significantly associated with shorter disease free survival time. (B) The correlation between MCM1-10 expression and overall survival time. The higher levels of MCM2, 4, 8, and 10 were markedly corrected with poorer outcome.](pone.0164150.g002){#pone.0164150.g002}

10.1371/journal.pone.0164150.t004

###### Survival outcomes.

![](pone.0164150.t004){#pone.0164150.t004g}

              Univariable analysis   Multivariable analysis                                  
  ----------- ---------------------- ------------------------ ------- ------- -------------- -------
  MCM1        0.784                  0.509--1.207             0.270                          
  MCM2        1.786                  1.154--2.734             0.009   1.322   0.700--2.498   0.389
  MCM3        1.16                   0.754--1.783             0.500                          
  MCM4        1.805                  1.159--2.809             0.009   1.240   0.684--2.248   0.478
  MCM5        1.349                  0.876--2.076             0.174   1.126   0.687--1.845   0.639
  MCM6        1.353                  0.880--2.079             0.169   0.565   0.309--1.035   0.065
  MCM7        1.201                  0.780--1.850             0.405                          
  MCM8        1.895                  1.227--2.928             0.004   1.707   1.047--2.863   0.032
  MCM9        1.108                  0.720--1.707             0.640                          
  MCM10       1.818                  1.176--2.811             0.007   1.588   0.881--2.863   0.124
  Age         1.456                  0.942--2.250             0.091   1.448   0.917--2.288   0.112
  Gender      0.934                  0.608--1.434             0.755                          
  HS          1.556                  0.990--2.445             0.055   1.172   0.725--1.895   0.517
  N stage     2.001                  1.193--3.358             0.009   1.169   0.358--2.816   0.796
  T stage     2.396                  1.186--4.838             0.015   1.383   0.621--3.080   0.427
  TMN stage   2.323                  1.333--4.046             0.003   2.052   0.557--7.554   0.280

CI, confidence interval; HR, hazard ratio; HS, Histology stage.

Discussion {#sec013}
==========

PC is a digestive malignancy with extremely high mortality and less therapeutic options. At present the most urgent work for this disease is to investigate novel and efficient biomarkers for prognosis and therapy \[[@pone.0164150.ref019]\]. In this study, we explored the roles of MCMs in PC for the first time. MCMs abnormal over-expression was significantly associated with PC progression, aggressive PC cell behaviors, poorer disease free survival, and poorer overall survival.

It has been reported thatMCM2-7 complex could work together as DNA helicases to promote the initial stage of DNA replication through participating the formation of pre-replication complex \[[@pone.0164150.ref020]--[@pone.0164150.ref022]\]. Once binding with some crucial factors in cell cycle (such as Cdc6, Cdt1, and Dbf4/Cdc7), MCM2-7 complex was activated to further enhance DNA synthesis by triggering DNA unwind \[[@pone.0164150.ref023]--[@pone.0164150.ref025]\]. In other words, MCM2-7 complex could promote cell cycle from S phase to G2/M phase, and finally enhance cell proliferation. Our analytic results also revealed MCM2-7 complex was very important in S phase. The expression of all members of MCM2-7 complex was positively associated with that of S phase biomarkers (CDK1 and CCNB1), as well as cell proliferation biomarker (Ki-67). However, there was no connection between MCM2-7 complex and PC cell migration, invasion, and EMT. Furthermore, MCM2-7 complex members were abnormally up-regulated in various cancers, such as gastric cancer and colon cancer. And they could be regarded as indicators for certain cancer progression and prognosis \[[@pone.0164150.ref026], [@pone.0164150.ref027]\].Our results also suggested that some members of MCM2-7 complex could predict PC progression (MCM4 for T stage). In accordance with the data provided by several past studies in other malignancies, PC patients with higher levels of MCM2, MCM4 and MCM 6 had poorer outcomes (MCM2, 4, and 6 for disease free survival time and MCM2 and 2 for overall survival time). However, none of them was an independent predictor of worse outcome.

There were other four members belong to MCM family, including MCM1, 8, 9, and 10. All of these four molecules were identified as critical factors in the regulation of cell cycle through different mechanisms. MCM1 could activate many immediate-early genes to further perform its function by interacting with serum response element \[[@pone.0164150.ref028], [@pone.0164150.ref029]\].As reported, the interaction between MCM8and CDC6 couldeffectively accelerate pre-replication complex assembly \[[@pone.0164150.ref030]\], as well as MCM9 and Cdt1 interaction \[[@pone.0164150.ref031]\]. It has also been reported that MCM8 and MCM9 could form a complex to facilitate homologous recombination which was mediated by RAD51 recruitment at DNA damage sites \[[@pone.0164150.ref032]\]. MCM10 was reported to promote chromosome replication by enhancing the assembly of the Cdc45-Mcm2-7-GINS complex \[[@pone.0164150.ref033]\]. And MCM10-RECQ4 interaction was necessary for this process \[[@pone.0164150.ref034]\]. All reported results above revealed that these four MCMs could also promote cell proliferation by influencing cell cycle. Our analytic data were similar to the report of literatures that MCM8-10 were positively correlated with biomarkers for S phase and cell proliferation in different degrees. Furthermore, many articles focused on these MCMs in malignancies demonstrated that their over-expression was significantly associated with clinicopathologic features for disease progression \[[@pone.0164150.ref017], [@pone.0164150.ref035], [@pone.0164150.ref036]\]. However, we just found that MCM9 over-expression was markedly associated lymph node metastasis of PC. Moreover, the prognostic values of MCM8 and MCM10 in PC were similar to MCM2 and MCM4, and MCM8 could be regarded as an independent prognostic factor for PC patients.

Furthermore, latest studies revealed that suppression of the MCMs could sensitize cancer cells to chemotherapeutic agents by inhibiting replicative fork progression, for example, gemcitabine and 5-Fluorouracil \[[@pone.0164150.ref037]\]. Therefore, we assessed the association between MCMs and gemcitabine resistance biomarkers. Meaningly, MCM2-7 complex expression was significantly associated with gemcitabine resistance biomarker RRM1, especially MCM2 and MCM4 which has high association with RRM1. And then, MCM7 and MCM9 was also moderately associated with RRM1. According to these results, we proposed a hypothesis that gemcitabine resistance might be improved after some MCMs down-regulation.

Conclusion {#sec014}
==========

In conclusion, abnormally up-regulated MCMs in PC were significantly associated with cancer cell proliferation, gemcitabine resistance, disease progression, and poorer outcomes. These results suggested that MCMs were potential biomarkers for PC progression and prognosis, and MCMs could also be considered as targets to improve the efficiency of gemcitabine-based therapy.
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======================

###### The primary data of MCM1-10 expression.
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Click here for additional data file.

###### The survival and clinicopathologic information of PC patients enrolled in this study.
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Click here for additional data file.

###### The primary data of some cancer biomarkers expression.
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Click here for additional data file.

The results shown here are in whole or part based upon data generated by the TCGA Research Network: <http://cancergenome.nih.gov/>.
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